文献速递乳腺癌

三阴性乳腺癌化疗耐药与应答的蛋白质基因组标志物

Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer.
PubMed 文献 · Cancer Discov · 2022-01-01

该研究采用微量蛋白质基因组学分析三阴性乳腺癌(TNBC)新辅助卡铂联合多西他赛化疗前活检标本,发现氧化磷酸化、脂肪生成和脂肪酸代谢通路与耐药相关,DNA修复、E2F靶点、G2-M检查点、干扰素γ信号及免疫检查点成分升高标志敏感。19q13.31-33缺失(含LIG1、POLD1、XRCC1)与耐药相关,LIG1缺失或低表达与病理完全缓解缺失、高染色体不稳定性指数及不良预后相关。

要点

  • 蛋白质组学揭示氧化磷酸化、脂肪生成和脂肪酸代谢通路与TNBC新辅助卡铂联合多西他赛耐药相关。
  • DNA修复、E2F靶点、G2-M检查点、干扰素γ信号和免疫检查点成分升高标志化疗敏感。
  • 19q13.31-33缺失(含LIG1、POLD1、XRCC1)与耐药相关,LIG1缺失或低表达与病理完全缓解缺失、高CIN及不良预后相关。

核心结论

  • 蛋白质基因组学分析揭示TNBC化疗应答相关的复杂分子景观,包括19q13.31-33体细胞缺失编码滞后链DNA合成基因(LIG1、POLD1、XRCC1),与病理应答缺失、卡铂选择性耐药相关,并在泛癌研究中与不良预后和CIN相关。

研究设计与样本

  • 采用微量蛋白质基因组学分析TNBC患者新辅助卡铂联合多西他赛化疗前活检标本,并在正交数据集中验证。

主要发现

  • 治疗前活检蛋白质组分析独特揭示氧化磷酸化、脂肪生成和脂肪酸代谢通路与耐药相关。
  • 蛋白质组学和转录组学均显示敏感性与DNA修复、E2F靶点、G2-M检查点、干扰素γ信号和免疫检查点成分升高相关。
  • 体细胞拷贝数畸变的蛋白质基因组分析识别出耐药相关的19q13.31-33缺失,该区域包含LIG1、POLD1和XRCC1。
  • 在正交数据集中,LIG1基因缺失和/或低mRNA表达水平与TNBC病理完全缓解缺失、更高染色体不稳定性指数(CIN)和不良预后相关,以及TNBC临床前模型中的卡铂选择性耐药相关。
  • LIG1半合子缺失也与其他癌症类型中更高CIN和不良预后相关,显示更广泛的临床意义。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Microscaled proteogenomics was deployed to probe the molecular basis for differential response to neoadjuvant carboplatin and docetaxel combination chemotherapy for triple-negative breast cancer (TNBC). Proteomic analyses of pretreatment patient biopsies uniquely revealed metabolic pathways, including oxidative phosphorylation, adipogenesis, and fatty acid metabolism, that were associated with resistance. Both proteomics and transcriptomics revealed that sensitivity was marked by elevation of DNA repair, E2F targets, G2-M checkpoint, interferon-gamma signaling, and immune-checkpoint components. Proteogenomic analyses of somatic copy-number aberrations identified a resistance-associated 19q13.31-33 deletion where LIG1, POLD1, and XRCC1 are located. In orthogonal datasets, LIG1 (DNA ligase I) gene deletion and/or low mRNA expression levels were associated with lack of pathologic complete response, higher chromosomal instability index (CIN), and poor prognosis in TNBC, as well as carboplatin-selective resistance in TNBC preclinical models. Hemizygous loss of LIG1 was also associated with higher CIN and poor prognosis in other cancer types, demonstrating broader clinical implications. SIGNIFICANCE: Proteogenomic analysis of triple-negative breast tumors revealed a complex landscape of chemotherapy response associations, including a 19q13.31-33 somatic deletion encoding genes serving lagging-strand DNA synthesis (LIG1, POLD1, and XRCC1), that correlate with lack of pathologic response, carboplatin-selective resistance, and, in pan-cancer studies, poor prognosis and CIN. This article is highlighted in the In This Issue feature, p. 2483.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Anurag M, Jaehnig EJ, Krug K, et al. Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer. Cancer Discov. 2022. PMID: 36001024. doi:10.1158/2159-8290.CD-22-0200

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。